Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
San Diego Convention Center, San Diego, CaliforniaNovember 01, 2023 - November 05, 2023
The SITC Annual Meeting brought together a global community of scientists focused on cancer immunotherapy and tumor immunology. Check out our poster presentations from the event and explore our immune checkpoint reporter cells, CAR-T luciferase reporter cells, THP-1 reporter cells, 2-D and 3-D patient-derived cancer models, human primary cells, and cancer panels to see how we can support your work!
Did you miss us at booth #731 and want to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.
Check out our poster presentations
Optimizing ex vivo CAR-T cell-mediated cytotoxicity assay through multimodality imaging
Presenter: John Foulke, MS, Lead Biologist, ATCC
Date: Friday, November 3, 2023
Time: 9:00 AM – 7:00 PM
Abstract number: 81
GAS-Luc2 reporter cell lines for immune checkpoint drug screening in solid tumors
Presenter: Hyeyoun Chang, PhD, Scientist, ATCC
Date: Saturday, November 4, 2023
Time: 9:00 AM – 7:00 PM
Abstract number: 496
Meet the presenters
John Foulke, MS
Lead Biologist, ATCC
John Foulke is a Lead Biologist in the Immuno-Oncology group in the R&D department at ATCC. John joined the ATCC cell biology R&D group in 2008, and he has led many projects centered on the development of novel cell lines and cell-based reporter systems to support cancer research community. His work is mainly focused on developing innovative cell models for research and drug discovery in the immuno-oncology field.
Hyeyoun Chang, PhD
Hyeyoun Chang, PhD, is a Scientist in the Immuno-oncology group of the R&D department at ATCC. She has extensive experience in the fields of biomedical engineering and cancer biology that focuses on drug delivery, intracellular signaling, and gene therapy. Prior to joining ATCC, Dr. Chang received her PhD in biomedical engineering from Korea University of Science and Technology and completed her postdoctoral training at Dana-Farber Cancer Institute/ Harvard Medical School.
Explore our featured immuno-oncology products
Checkpoint luciferase reporter cells
Facilitate therapeutic development with luciferase reporter cells that endogenously express immune checkpoint molecules.Order the reporter models
CAR-T target luciferase reporter cells
Accelerate CAR-T therapy development with luciferase reporter solid and liquid tumor cell lines that express surface tumor antigens.Get CAR-T Target Luciferase Cells
THP-1 reporter cells
ATCC offers luciferase reporters containing the response element of immunologically important transcription factors into the THP-1 cell line.Order THP-1 reporter cell lines
Primary human immune cells
ATCC primary immune cells are able to support complex physiologically relevant research projects, including cancer immunology studies.Order primary immune cells
Immunology research tools
Our collection includes immune cells, CD34+ and CD14+ progenitor cells, primary mononuclear cells, lymphocytes, and leukocytes.Find immune cells
ATCC has a wide selection of hybridomas that secrete antibodies targeting specific cellular epitopes.Explore hybridomas
Contact us today!
Your ATCC sales representative stands ready to discuss your research needs and provide you with personalized care in sourcing reference materials, managing requests, and providing sales quotes. Please complete our form to let us know how we can help, and we will start working on your needs right away.